Literature DB >> 32084597

Appropriate and inappropriate shocks in hypertrophic cardiomyopathy patients with subcutaneous implantable cardioverter-defibrillators: An international multicenter study.

Babak Nazer1, Zack Dale2, Gianmarco Carrassa3, Nosheen Reza4, Tuna Ustunkaya4, Nikolaos Papoutsidakis5, Andrew Gray2, Stacey J Howell2, Miriam R Elman2, Paolo Pieragnoli3, Giuseppe Ricciardi3, Daniel Jacoby5, David S Frankel4, Anjali Owens4, Iacopo Olivotto3, Stephen B Heitner2.   

Abstract

BACKGROUND: Subcutaneous implantable cardioverter-defibrillators (S-ICDs) are attractive for preventing sudden cardiac death in hypertrophic cardiomyopathy (HCM) as they mitigate risks of transvenous leads in young patients. However, S-ICDs may be associated with increased inappropriate shock (IAS) in HCM patients.
OBJECTIVE: The purpose of this study was to assess the incidence and predictors of appropriate shock and IAS in a contemporary HCM S-ICD cohort.
METHODS: We collected electrocardiographic and clinical data from HCM patients who underwent S-ICD implantation at 4 centers. Etiologies of all S-ICD shocks were adjudicated. We used Firth penalized logistic regression to derive adjusted odds ratios (aORs) for predictors of IAS.
RESULTS: Eighty-eight HCM patients received S-ICDs (81 for primary and 7 for secondary prevention) with a mean follow-up of 2.7 years. Five patients (5.7%) had 9 IAS episodes (3.8 IAS per 100 patient-years) most often because of sinus tachycardia and/or T-wave oversensing. Independent predictors of IAS were higher 12-lead electrocardiographic R-wave amplitude (aOR 2.55 per 1 mV; 95% confidence interval 1.15-6.38) and abnormal T-wave inversions (aOR 0.16; 95% confidence interval 0.02-0.97). There were 2 appropriate shocks in 7 secondary prevention patients and none in 81 primary prevention patients, despite 96% meeting Enhanced American College of Cardiology/American Heart Association criteria and the mean European HCM Risk-SCD score predicting 5.7% 5-year risk. No patients had sudden death or untreated sustained ventricular arrhythmias.
CONCLUSION: In this multicenter HCM S-ICD study, IAS were rare and appropriate shocks confined to secondary prevention patients. The R-wave amplitude increased IAS risk, whereas T-wave inversions were protective. HCM primary prevention implantable cardioverter-defibrillator guidelines overestimated the risk of appropriate shocks in our cohort.
Copyright © 2020 Heart Rhythm Society. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Hypertrophic cardiomyopathy; Inappropriate shocks; Risk stratification; Subcutaneous implantable cardioverter-defibrillator; Sudden cardiac death

Year:  2020        PMID: 32084597      PMCID: PMC8052990          DOI: 10.1016/j.hrthm.2020.02.008

Source DB:  PubMed          Journal:  Heart Rhythm        ISSN: 1547-5271            Impact factor:   6.343


  25 in total

1.  2011 ACCF/AHA guideline for the diagnosis and treatment of hypertrophic cardiomyopathy: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.

Authors:  Bernard J Gersh; Barry J Maron; Robert O Bonow; Joseph A Dearani; Michael A Fifer; Mark S Link; Srihari S Naidu; Rick A Nishimura; Steve R Ommen; Harry Rakowski; Christine E Seidman; Jeffrey A Towbin; James E Udelson; Clyde W Yancy
Journal:  J Thorac Cardiovasc Surg       Date:  2011-12       Impact factor: 5.209

2.  A novel clinical risk prediction model for sudden cardiac death in hypertrophic cardiomyopathy (HCM risk-SCD).

Authors:  Constantinos O'Mahony; Fatima Jichi; Menelaos Pavlou; Lorenzo Monserrat; Aristides Anastasakis; Claudio Rapezzi; Elena Biagini; Juan Ramon Gimeno; Giuseppe Limongelli; William J McKenna; Rumana Z Omar; Perry M Elliott
Journal:  Eur Heart J       Date:  2013-10-14       Impact factor: 29.983

3.  Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction.

Authors:  Arthur J Moss; Wojciech Zareba; W Jackson Hall; Helmut Klein; David J Wilber; David S Cannom; James P Daubert; Steven L Higgins; Mary W Brown; Mark L Andrews
Journal:  N Engl J Med       Date:  2002-03-19       Impact factor: 91.245

4.  Complications involving the subcutaneous implantable cardioverter-defibrillator: Lessons learned from MAUDE.

Authors:  Emily P Zeitler; Daniel J Friedman; Zak Loring; Kristen B Campbell; Sarah A Goldstein; Zachary K Wegermann; Jane Schutz; Nicole Smith; Eric Black-Maier; Sana M Al-Khatib; Jonathan P Piccini
Journal:  Heart Rhythm       Date:  2019-09-24       Impact factor: 6.343

Review 5.  2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.

Authors:  Sana M Al-Khatib; William G Stevenson; Michael J Ackerman; William J Bryant; David J Callans; Anne B Curtis; Barbara J Deal; Timm Dickfeld; Michael E Field; Gregg C Fonarow; Anne M Gillis; Christopher B Granger; Stephen C Hammill; Mark A Hlatky; José A Joglar; G Neal Kay; Daniel D Matlock; Robert J Myerburg; Richard L Page
Journal:  Heart Rhythm       Date:  2017-10-30       Impact factor: 6.343

6.  Inappropriate shocks in the subcutaneous ICD: Incidence, predictors and management.

Authors:  Louise R A Olde Nordkamp; Tom F Brouwer; Craig Barr; Dominic A M J Theuns; Lucas V A Boersma; Jens B Johansen; Petr Neuzil; Arthur A M Wilde; Nathan Carter; Michael Husby; Pier D Lambiase; Reinoud E Knops
Journal:  Int J Cardiol       Date:  2015-05-22       Impact factor: 4.164

7.  Prevalence of subcutaneous implantable cardioverter-defibrillator candidacy based on template ECG screening in patients with hypertrophic cardiomyopathy.

Authors:  Niccolo' Maurizi; Iacopo Olivotto; Louise R A Olde Nordkamp; Katia Baldini; Carlo Fumagalli; Tom F Brouwer; Reinoud E Knops; Franco Cecchi
Journal:  Heart Rhythm       Date:  2015-09-08       Impact factor: 6.343

8.  International External Validation Study of the 2014 European Society of Cardiology Guidelines on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy (EVIDENCE-HCM).

Authors:  Constantinos O'Mahony; Fatima Jichi; Steve R Ommen; Imke Christiaans; Eloisa Arbustini; Pablo Garcia-Pavia; Franco Cecchi; Iacopo Olivotto; Hiroaki Kitaoka; Israel Gotsman; Gerald Carr-White; Jens Mogensen; Loizos Antoniades; Saidi A Mohiddin; Mathew S Maurer; Hak Chiaw Tang; Jeffrey B Geske; Konstantinos C Siontis; Karim D Mahmoud; Alexa Vermeer; Arthur Wilde; Valentina Favalli; Oliver P Guttmann; Maria Gallego-Delgado; Fernando Dominguez; Ilaria Tanini; Toru Kubo; Andre Keren; Teofila Bueser; Sarah Waters; Issa F Issa; James Malcolmson; Tom Burns; Neha Sekhri; Christopher W Hoeger; Rumana Z Omar; Perry M Elliott
Journal:  Circulation       Date:  2017-11-30       Impact factor: 29.690

9.  Inappropriate subcutaneous implantable cardioverter-defibrillator therapy due to R-wave amplitude variation: Another challenge in device management.

Authors:  Syeda A Batul; Felix Yang; Karan Wats; Suvash Shrestha; Yisachar J Greenberg
Journal:  HeartRhythm Case Rep       Date:  2016-09-28

10.  Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy: Insights from the Sarcomeric Human Cardiomyopathy Registry (SHaRe).

Authors:  Carolyn Y Ho; Sharlene M Day; Euan A Ashley; Michelle Michels; Alexandre C Pereira; Daniel Jacoby; Allison L Cirino; Jonathan C Fox; Neal K Lakdawala; James S Ware; Colleen A Caleshu; Adam S Helms; Steven D Colan; Francesca Girolami; Franco Cecchi; Christine E Seidman; Gautam Sajeev; James Signorovitch; Eric M Green; Iacopo Olivotto
Journal:  Circulation       Date:  2018-08-23       Impact factor: 29.690

View more
  1 in total

1.  A real-world experience of subcutaneous and transvenous implantable cardiac defibrillators-comparison with the PRAETORIAN study.

Authors:  Dibbendhu Khanra; Abdul Hamid; Peysh Patel; John Tomson; Ahmed Abdalla; Nasrin Khan; Rory Dowd; Nakul Chandan; Christopher Osagie; Tomilola Jinadu; Selvakumar Velu; Anita Arya; Charles Spencer; Craig Barr; Sanjiv Petkar
Journal:  J Arrhythm       Date:  2022-02-21
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.